Chemical | 01 April 2021
Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The chemical business of the Mawana Sugar Limited stands fully transferred to Bodal Chemical Limited with effect from March 31, 2021
The company has accorded its consent to sell the Ongole plant which is inclusive of land, building, machinery, and other assets
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
The greenfield facility will have a total installed capacity of 132,500 MTPA, enhancing the total capacity by 2.1x to 252,500 MTPA
Being the world’s second-largest emerging market, India must partner with the EU which is playing a key role in chemical sector transformation
Tailor-made pigments for the various levels of heat stability required
The adhesive technologies business unit is expected to achieve an organic sales growth of around 12.5 percent.
New testing confirms ActizoneF5 delivers outstanding antiviral surface protection for 24 hours against enveloped viruses like SARS-CoV-2
The domestic industry continues to suffer material injury on account of dumped imports
India produces 60% of the world’s vaccine
Base material for the production of the housing is a thermoplastic composite from the LANXESS Tepex dynalite product range
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
_256_384.jpg)
On a year-over-year (Y/Y) basis, the barometer rose 5.5% in March
To invest in incremental capacity expansions across its network including further investment in Asia to support local innovation.
The China centre will strengthen local innovation and foster agile collaboration with customers
The company had filed a suit in the High Court of Justice, Ghana
.jpg)
Future growth depends on policy changes related to trade, marketing, production, manufacturing, IPR, and product registration
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Despite volatility in prices of crude oil and crude oil derivatives, UPL has maintained its EBITDA margin in a narrow range of 17.5-20.4% over FY09-FY21E
Subscribe to our newsletter & stay updated.
_IndianOil_256_275.jpg)
